One of the hallmarks of AIDS has been the elevated risk of developing cancers linked to immunosuppression. The introduction of highly active antiretroviral therapy (HAART) has greatly changed the natural history of HIV infection and associated morbidities. In Western countries the cumulative risk of developing and dying from AIDS defining cancers (ADCs) such as Kaposi’s sarcoma, non-Hodgkin’s lymphoma (NHL) and invasive cervical cancer, has significantly declined. On the other hand, non-AIDS-defining cancers (NADCs), such as hepatocellular carcinoma, anal cancer, lung cancer significantly increased.
Cancers therefore still represent a significant burden of HIV-associated morbidity in the current era of HAART worldwide. Few studies have highlighted clearly the impact of scale up of HAART on cancer burden in resource-limited settings such as in Sub-Saharan Africa. It is prudent to state that the highest burden of HIV and cancers are currently found in these countries. It is ironic that in practice linkage between HIV and cancers at this point in LMIC is based on extrapolation from the developed world experience. This has probably contributed to the challenges being faced in translating this model for intervention in LMIC. The resources available and background cancer risks factors in these two settings are diametrical at best.
By and large, the epidemiology of malignancies in the developing world are driven by infectious agents mainly viruses such Human Herpes virus 8(HHV8), Epstein Barr Virus (EBV), human papilloma virus (HPV) infection and hepatitis B and C (HBV and HCV). The observations from these countries still show that the cancers common in HIV-infected individual are very much reminiscent of the era before wide spread use of HAART; given the magnitude of AIDS-defining cancers such as Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer.
There is therefore need to better understand the impact of HAART optimization on cancer burden and picture in LMIC. In doing this there must be tools and means for assessing the potential impact of optimized care in LMIC. This may include implementation of interventions that incorporate strategies for both ADC and NADC. Research aimed at understanding local situation but also answering global questions on HIV and cancers at this point can best be done in LMIC. The critical requirement for this undertaking in LMIC must emphasize infrastructure and human capacity development in these countries.